Regeneron Just Bought Your DNA From 23andMe
Digest more
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.
Genetic testing company 23andMe is being acquired, shortly after it declared bankruptcy months ago.
Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles including a data breach.
2d
Stocktwits on MSNRegeneron To Buy Assets Of 23andMe For $256M: Retail Says ‘Fantastic’ For Future R&D EffortsDrugmaker Regeneron Pharmaceuticals, Inc. (REGN) said on Monday that it will acquire the assets of bankrupt biotechnology company 23andMe Holding Co. for $256 million. Regeneron intends to acquire 23andMe’s Personal Genome Service (PGS),